Adoptive immunotherapy with donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (alloSCT) may not only mediate Graft-versus-Leukemia (GvL) reactivity, but also induce Graft-versus-Host Disease (GvHD). As HLA-class II molecules are predominantly expressed on hematopoietic cells, CD4 þ T cells may selectively mediate GvL reactivity without GvHD. Here, we assessed the capacity of human CD4 þ T cells to act as sole mediators of GvL reactivity in a NOD/scid mouse model for human acute lymphoblastic leukemia and chronic myeloid leukemia in lymphoid blast crisis. Highly purified CD4 þ DLI eradicated the leukemic cells. The anti-tumor immunity was mediated by a polyclonal CD4 þ T cell response comprising cytokine-producing T-helper and cytolytic T-effector cells directed against the mismatched HLA-class II molecules of the patients. Furthermore, primary leukemic cells acquired an antigen-presenting cell (APC) phenotype in vivo after DLI, as well as in vitro after co-culture with leukemia-specific CD4 þ T cells. In conclusion, our results show that CD4 þ T cells can be strong mediators of anti-tumor immunity, and provide evidence that cross-talk between CD4 þ T cells and leukemic cells is the basis for induction of leukemic cells with an APC phenotype. These data emphasize the clinical relevance of CD4 þ T cell based immunotherapy as treatment modality for hematological malignancies after alloSCT.
Introduction
Donor T cells recognizing allo-antigens on recipient cells have an important role in both Graft-versus-Leukemia (GvL) reactivity and Graft-versus-Host Disease (GvHD) after allogeneic stem cell transplantation (alloSCT). Depletion of T cells from the stem cell graft is an efficient method to prevent GvHD, but it also adversely affects posttransplant anti-tumor and anti-viral immunity.
1,2 Subsequent donor lymphocyte infusion (DLI) can induce sustained complete remissions of hematological malignancies, but GvHD remains a significant cause of morbidity and mortality. 3, 4 As only 30% of patients have an HLA-identical sibling, the majority of alloSCT are performed with stem cell grafts from unrelated donors (URD). 5 To prevent severe GvHD, patients and donors are preferably matched for HLA-A, -B, -C, and -DR. Disparity in HLA antigens between donor and recipient increases the risk of severe GvHD owing to high frequencies of allo-reactive donor T cells recognizing recipient mismatched HLA alleles. Because HLA-class I molecules are constitutively expressed on all nucleated cells, CD8 þ cells recognizing alloantigens in the context of HLA-class I molecules may mediate severe GvHD, and, therefore, mismatching for HLA-class I molecules is preferentially avoided. In contrast to HLA-class I, constitutive expression of HLA-class II molecules is mainly confined to hematopoietic cells, and expression on nonhematopoietic cells is mainly induced under inflammatory conditions. 6 Because of this different expression pattern, disparity for HLA-class II molecules may induce a more selective GvL effect as compared with HLA-class I incompatibility. Mismatching for HLA-class II molecules at the time of alloSCT, when high levels of proinflammatory cytokines are produced, has demonstrated to be associated with GvHD. However, we have previously demonstrated that, in the absence of an inflammatory environment, HLA-DP-specific allo-reactive CD4 þ T cells mediated a strong GvL response with only minimal skin GvHD in a patient who responded to unmodified DLI administered late after HLA-DP mismatched T cell depleted alloSCT. 7 Development of GvL reactivity and GvHD is therefore likely to depend on the expression pattern of HLA-DR, -DQ and -DP molecules on normal and malignant cells that may be variable under different clinical circumstances. Therefore, insight into the contribution of HLA-class II molecules to GvL reactivity and GvHD is relevant for optimal design of CD4 þ T cell based immunotherapies after HLA-class II mismatched alloSCT.
Traditionally, CD8 þ T cells are considered potent effector cells of anti-tumor responses, whereas CD4 þ T cells are required as helper cells in the induction and maintenance of CD8 þ T cell immunity. [8] [9] [10] [11] However, CD4 þ T cells with direct cytolytic activity against leukemic cells have been isolated from patients with GvL responses, suggesting that CD4 þ T cells may also contribute to anti-tumor immunity as effector cells. 7, [12] [13] [14] This is also supported by clinical studies, which showed that depletion of CD8 þ T cells from the stem cell graft or DLI reduced the incidence and severity of GvHD without compromising GvL reactivity. 15, 16 However, although these studies have demonstrated clinical efficacy of CD8-depleted DLI, it remains unclear whether clinical responses in these patients were directly mediated by CD4 þ T cells, or could be attributed to contaminating CD8 þ T cells in the DLI or residual donor-derived CD8 þ T cells in the patients. Donorderived CD8 þ T cells have been reported as the prominent effector cells mediating GvL reactivity in a chronic myeloid leukemia (CML) patient who responded to CD8-depleted DLI. 17 DLI administered to patients with relapsed leukemia after alloSCT is successful in CML in chronic phase with 60-80% induction of complete remissions.
3,4,18 However, clinical responses in patients with CML in accelerated phase or blast crisis, acute myeloid leukemia and acute lymphoblastic leukemia (ALL) are only 10-30%. 3, 4, 18 The low efficacy of DLI in these patients may be attributed to the progressive nature of these malignancies but may also illustrate their diminished capacity to elicit effective immune responses in vivo. It is known that antigen-presenting cells (APC) are required for efficient induction of anti-tumor immunity in vivo, and that APC acquire a mature phenotype on interaction with T-helper cells. [8] [9] [10] 19 In vitro, in the presence of a variety of soluble factors, various types of leukemic cells, including CML, 20, 21 acute myeloid leukemia, [21] [22] [23] ALL 21, 22 and chronic lymphocytic leukemia, 21, 24 cells have been shown to differentiate into leukemic-APC displaying increased expression of HLA-class II, adhesion and costimulatory molecules and an enhanced capacity to stimulate allogeneic T cell responses. [20] [21] [22] [23] [24] On the basis of these findings, it can be speculated that the efficacy of DLI depends on the capacity of leukemic cells to become leukemic-APC in vivo.
In this study, we assessed the capacity of immunotherapy with human CD4 þ T cells to mediate GvL reactivity in a NOD/scid mouse model for human ALL and CML in lymphoid blast crisis in three HLA-class II mismatched settings. Our data show that highly purified CD4 þ T cells efficiently eradicated leukemic cells and that HLA-DR, -DQ, and -DP-specific T cells contributed to the GvL effect. Furthermore, the leukemic cells were shown to acquire an APC phenotype in vivo after treatment with DLI. Our data therefore demonstrate that CD4 þ T cells can act as sole mediators of anti-tumor immunity by targeting various HLA-class II molecules as helper as well as effector cells, and imply that cross-talk between leukemic cells and CD4 þ T cells in vivo is the basis for induction of leukemic cells with APC phenotype and efficient anti-tumor immunity.
Materials and methods

Patient and donor samples
Bone marrow (BM) and peripheral blood (PB) samples were obtained from patients and healthy URD after informed consent, according to the Declaration of Helsinki and cryopreserved. Leukemic cells were obtained from patients with precursor-B ALL (patients 1 and 2) and CML in lymphoid blast crisis (patient 3). HLA typing was performed by standard serology methods and sequence-specific polymerase chain reactions (Supplementary Table 1 ).
Isolation of T cells for DLI
CD3 þ T cells were isolated from donor PB mononuclear cells using the pan T isolation kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to manufacturer's instructions, and used for CD3 þ DLI. For CD4 þ DLI from URD1 and URD2, CD8 þ T cells were depleted from CD3 þ T cells using magnetic CD8 microbeads (Miltenyi Biotec GmbH). For CD4 þ DLI's from URD3, CD3 þ T cells were stained with FITClabeled CD4 (Becton Dickinson (BD), San Jose, CA, USA) and PE-labeled CD8 (Caltag, Invitrogen, Oslo, Norway) monoclonal antibodies (moAb) and CD4 þ CD8À T cells were sorted by flowcytometry. The purity of isolated fractions was analyzed after staining with FITC-labeled CD4, PE-labeled CD8 and PECy5-labeled CD3 (BD) moAb.
In vivo NOD/scid mouse experiments
Female NOD/scid mice aged 5-6 weeks were purchased from Charles River (Saint-Germain-sur-l'Abresle, France). Animal experiments were approved by the Institutional Animal Care and Use Committee. Mice were engrafted with primary human leukemic cells and monitored, as described previously. 25 Briefly, following intravenous injection of leukemic cells, engraftment of leukemia was monitored by flowcytometric analysis of PB samples after staining with FITC-labeled human CD19 (BD) and PE-labeled mouse CD45 (Ly5, Caltag). On detection of leukemic cells in PB (1-5%), mice were left untreated or were treated with CD3 þ or CD4 þ DLI from URD (see legend Figure 1 for details). After DLI, PB samples were analyzed for the presence of leukemic cells and T cells by flowcytometry after staining with FITC-labeled CD19 and CD4, PE-labeled CD8 and PECy5-labeled CD3 human moAb. At killing, absolute leukemic cell numbers were determined in BM and spleens of all mice, and inter-treatment differences were tested for significance by performing a Mann-Whitney U-test.
Ex vivo phenotypical analysis of leukemic cells and T cells
Phenotypical analysis of leukemic cells was performed by staining BM or spleen samples of mice with APC-labeled CD19, FITC-labeled CD40 (AbD Serotec, Brentwood, CA, USA), CD54 (CLB, Amsterdam, the Netherlands) and CD58 (Southern Biotech, Birmingham, UK), and PE-labeled HLA-DR (BD), HLA-DQ (Biodesign International, Saco, ME, USA), HLA-DP (Leinco Technologies, Cambridge, UK), CD80 (BD), CD83 (Caltag) and CD86 (BD) human moAb. Phenotypical analysis of T cells was performed by staining samples of mice with PerCPlabeled CD4 (BD) or CD8 (BD), FITC-labeled CCR7 (R&D Systems, Minneapolis, MN, USA), PE-labeled CD45RA, HLA-DR, CD25, CD38 (all BD) and CD69 (Caltag), and APC-labeled CD45RO (BD) human moAb.
Isolation of T cell clones
T cells were cloned by flowcytometric sorting or limiting dilution from BM, spleen and PB samples of mice engrafted with leukemic cells from all patients after treatment with CD4 þ DLI ( Table 1) . Cell suspensions were either stained with FITClabeled human CD4 moAb, and CD4 þ cells were sorted singlecell-per-well by flowcytometry into 96-wells plates containing irradiated (50 Gy) allogeneic PB mononuclear cells (0.5*10 5 / well) as feeder cells in 100 ml Iscoves modified dulbecco's medium (IMDM, BioWhittaker, Verviers, Belgium) with 5% human ABO serum and 5% fetal calf serum (FCS, BioWhittaker), IL2 (120 IU/ml) (Chiron, Amsterdam, the Netherlands) and phytohemagglutinin (0.8 mg/ml) (Murex Biotec Limited, Dartford, UK), or T cells were cloned by seeding T cells at limiting concentrations using the same feeder cells. Proliferating T cell clones restimulated every 10-20 days, as described above.
Target cells for functional studies
Epstein-Barr Virus (EBV)-transformed lymphoblastoid cell lines (EBV-LCL) were generated using standard procedures. Leukemic cells were modified into leukemic-APC, as previously described. 21 Briefly, primary leukemic cells were cultured in IMDM with 10% ABO serum, 500 IU/ml IL4 (Schering-Plough, Innishammon, Ireland) and 10 mg/ml synthetic CpG oligonucleotides (Eurogentec, Seraing, Belgium) followed by co-culturing on a monolayer of murine fibroblast cell line (Ltk-) transfected with human CD40-ligand (provided by Dr C van Kooten, LUMC, the Netherlands). Phenotypical analysis of in vitro generated leukemic-APC was performed as CD4 þ T cells as mediators of anti-tumor immunity S Stevanović et al described for leukemic cells directly ex vivo. Donor EBV-LCL and HLA-class II negative Hela cells were retrovirally transduced with the mismatched HLA-class II alleles of the patients as described previously. [26] [27] [28] Hela cells retrovirally transduced with the invariant chain (Ii chain) and HLA-DM were previously generated. 28 HLA-DRB1*1301, 29 -DRB3*0101, 29 -DPB1*0101, 28 -DPB1*0301 7 and -DPB1*0401 30 were cloned into MP71-IRES-NGFR, whereas HLA-DQB1*0603 and HLA-DPA1*0201 28 were cloned into LZRS-IRES-GFP. 26 Transduced cells with HLA-class II genes were isolated based on marker gene expression (NGFR and/or GFP) by magnetic beads (PE-labeled human NGFR moAb (Cedarlane laboratories, Burlington, VT, USA) and anti-PE-coated magnetic beads (Miltenyi Biotec GmbH) or by flowcytometry based on co-expression of GFP and NGFR.
Functional studies
For analysis of IFN-g production, CD4 þ T cell clones (5000 cells) were stimulated with primary leukemic cells, leukemic-APC or EBV-LCL (30 000 cells) in 150 ml IMDM with 5% ABO serum, 5% FCS and 10 IU/ml IL2 (culture medium). After overnight incubation at 37 1C 50 ml of supernatant was analyzed by IFN-g ELISA. Cytolytic activity of CD4 þ T cell clones against these target cells was determined using a 20 h 51 Cr release cytotoxicity assay. Target cells were labeled with Na 2 51 CrO 4 (Perkinelmer, Groningen, the Netherlands) for 1 h at 37 1C and incubated (2000 cells) with CD4 þ T cell clones at different effector to target ratios in 150 ml culture medium. After 20 h of incubation at 37 1C, 25 ml of supernatant was collected and measured in a luminescence counter (Topcount-NXT, Packard, USA). Cytokine release profile by CD4 þ T cell clones on 
Phenotypical analysis of in vitro induction of leukemic-APC
Phenotypical analysis of leukemic cells (20 000 cells) after 48 h incubation in culture medium supplemented with IFN-g (1 ng/ml; Boehringer Ingelheim, Alkmaar, the Netherlands), TNF-a (1 ng/ ml; Cellgenix, Freiburg, Germany) and/or IL-13 (1 ng/ml; Peprotech, Rocky Hill, USA), or in supernatant of activated CD4 þ T cells, was performed by flowcytometry, as described for leukemic cells ex vivo. For co-incubation with CD4 þ T cells, primary leukemic cells (20 000 cells) were incubated with CD4 þ T cell clones (5000-60 000 cells) in 150 ml culture medium, and after overnight or 48 h incubation, phenotypical analysis of leukemic cells was performed as described for leukemic cells ex vivo.
Results
In vivo induction of anti-tumor immunity after CD4 þ DLI
To investigate whether CD4 þ T cells can mediate anti-tumor responses, the efficacy of CD4 þ DLI was tested and compared with CD3 þ DLI in three independent experiments in NOD/scid mice engrafted with leukemic cells from different patients and treated with lymphocytes from various donors ( Table 1 and  Supplementary Table 1 ). After inoculation of primary leukemic cells from patients 1 and 2, mice were treated with CD3 þ or CD4 þ DLI purified using immunomagnetic beads. Mice that did not receive treatment served as controls. In mice treated with CD3 þ DLI, the infused T cell populations isolated from URD1 and URD2 consisted of CD4 þ and CD8 þ T cells. For CD4 þ DLI, CD8 þ T cells were depleted from CD3 þ T cells by magnetic beads, leading to T cell populations consisting of CD4 þ T cells with 0.7% and 0.3% contaminating CD8 þ T cells for URD1 and URD2, respectively (Table 1) . Progressive leukemic development was observed in control mice (Figure 1a) . In mice treated with CD3 þ or CD4 þ DLI, T cells appeared in PB between 9 to 13 days after DLI, and the Sacrificed for BM and spleen analysis (Figure 1d ).
c Died due to xenoreactivity (organs not available for analysis, therefore not included in Figure 1D ). f Killed for analysis of T cell reactivity (not included in Figure 1 ). CR ¼ complete remission, o0.5% CD19+ cells in peripheral blood. n.d. ¼ not determined, due to sacrifice of the mouse for analysis of T cell reactivity.
CD4 (Figures 1b and c ; Table 1 ). Despite rigorous depletion of CD8 þ T cells by magnetic beads for CD4 þ DLI from URD1 and URD2, low numbers of contaminating CD8 þ T cells were shown to expand in vivo, thereby prohibiting to draw definite conclusions as to whether anti-tumor responses were solely mediated by donor-derived CD4 þ T cells. Therefore, mice, engrafted with leukemic cells from patient 3, were treated with CD4 þ DLI from URD3 consisting of 99,7% CD4 þ T cells isolated by flowcytometry and no contaminating CD8 þ T cells. In mice treated with CD3 þ DLI (Figure 1b) and CD4 þ DLI (Figure 1c) , T cells emerged in PB 28 and 40 days after DLI, respectively. After CD3 þ DLI, CD4 þ as well as CD8 þ T cells were detected, whereas only CD4 þ T cells were measured after CD4 þ DLI (Table 1 ). Similar to mice engrafted with leukemic cells from patients 1 and 2, the emergence of T cells correlated with the occurrence of anti-tumor responses.
Following the disappearance of leukemic cells from PB in treated mice, T cell expansion stopped, and total T cell numbers started to decline (Figures 1b and c) . Mice treated with CD3 þ and CD4 þ DLI showed xenoreactive symptoms at this time point, resulting in death of mice (Table 1) . Ex vivo organ analyses of evaluable mice after CD3 þ and CD4 þ DLI showed significantly reduced numbers of leukemic cells in BM and spleens in comparison to control mice (Figure 1d ). The T cell composition in BM and spleens was similar as measured in PB (data not shown). In conclusion, based on the observation that in vivo expansion of CD4 þ T cells in leukemic NOD/scid mice after treatment with CD4 þ DLI coincided with the rapid disappearance of leukemic cells and the finding that CD4 þ T cells were the only human T cells detected after CD4 þ DLI from URD3, we conclude that CD4 þ T cells are capable of mediating anti-tumor responses.
Phenotypic analysis of the anti-tumor response
As in vivo experiments in Figure 1 demonstrated efficient induction of anti-tumor responses after DLI, and professional APC are generally believed to be required for efficient induction of anti-tumor immunity, we investigated the phenotype of leukemic cells in more detail. Ex vivo flowcytometric analyses were performed with BM or spleens from mice inoculated with leukemic cells from three patients after treatment with DLI. As a control, primary leukemic cells before inoculation and leukemic cells from BM or spleens from non-treated mice were analyzed. Flowcytometric analysis demonstrated upregulated expression of HLA-class II molecules and CD54 after CD3 þ and CD4 þ DLI, whereas the leukemic cells remained unchanged in nontreated mice. The median increase (range) of these molecules after CD3 þ DLI (n ¼ 4 mice) in comparison to untreated mice (n ¼ 4 mice) was 1.5-fold (1.2-1.7) for HLA-DR, 2.4-fold (2.3-3.3) for HLA-DQ, 2.0-fold (1.6-2.2) for HLA-DP and 3.6-fold (2.0-4.5) for CD54. After CD4 þ DLI (n ¼ 5 mice), the median increase (range) was 2.0-fold (1.7-3.9) for HLA-DR, 3.5-fold (2.3-15.5) for HLA-DQ, 2.3-fold (1.7-4.7) for HLA-DP and 6.5-fold (2.8-21.8) for CD54. Leukemic cells in mice treated with DLI showed variable expression of CD40, CD80 and CD86, while remaining negative for CD83 (data not shown). No substantial difference in leukemic-APC phenotype, after treatment with DLI, was observed between mice engrafted with leukemic cells from different patients. A representative example of phenotypic analysis is shown in Figure 2a . In addition, phenotypical analysis of in vivo expanded T cells, after treatment with DLI, was performed. Before infusion, CD4 þ T cells from all URD consisted of naive (CD45RA þ CCR7 þ ) and memory (CD45RO þ CCR7 þ and CD45RO þ CCR7À) T cells, and percentages of CD4 þ T cells expressing the activation markers HLA-DR, CD38 or CD69 were below 4, 40 and 10%, respectively. A similar phenotype was displayed by CD8 þ T cells before infusion (data not shown). After DLI, however, the majority of T cells emerging in the BM or spleens of analyzed mice displayed an activated (HLA-DR þ ) effectormemory (CD45RO þ CCR7-) phenotype (Figure 2b) . No difference in phenotype was observed between CD4 þ and CD8 þ T cells (data not shown). T cells were also shown to express PD-1 after DLI (data not shown), which has been described to indicate an exhausted T cell phenotype. The leukemic cells, however, did not express PDL-1 (data not shown), and, therefore, this inhibitory pathway is likely not to have a major role in the GvL efficacy of human DLI in our NOD/scid mouse model.
In conclusion, flowcytometric analysis demonstrated that leukemic cells acquired a leukemic-APC phenotype in vivo after DLI, and that T cells became strongly activated, indicating that cross-talk between T cells and leukemic cells coincided with anti-tumor immunity.
Functional analysis of the anti-tumor responses
To analyze the specificity of the anti-tumor responses in mice engrafted with leukemic cells from different patients after CD4 þ DLI from various URD, human CD4 þ T cells were clonally isolated from BM, PB and/or spleens of treated mice at the experimental end-point (patient 1 and 2) or during the anti-tumor response (patient 3) ( Table 1) . Expansion was observed for 27, 37 and 122 CD4 þ T cell clones isolated from mice engrafted with leukemic cells from patients 1, 2 and 3, respectively. As ex vivo flowcytometric analyses demonstrated that leukemic cells acquired an APC phenotype in vivo after treatment with DLI, we tested the reactivity of isolated CD4 þ T cell clones against primary leukemic cells as well as primary leukemic cells in vitro modified into leukemic-APC. In addition, reactivity against patient and donor EBV-LCL was analyzed. The majority of isolated T cell clones (patient 1: n ¼ 21 (78%); patient 2: n ¼ 27 (73%); patient 3: n ¼ 102 (84%)) showed specific production of IFN-g (430 pg/ml) on stimulation with leukemic-APC, but not donor EBV-LCL. Of these CD4 þ T cell clones, 5, 13 and 30 T cell clones from patients 1, 2 and 3, respectively, displayed strong reactivity against leukemic-APC (4250 pg/ml IFN-g), whereas low reactivity (o250 pg/ml IFN-g) was observed for 16, 14 and 72 T cell clones (Figure 3a and Supplementary Figure 1AB) . Of the T cell clones with strong reactivity against leukemic-APC, a number of T cell clones also showed strong recognition of patient EBV-LCL (4250 pg/ml IFN-g; patient 1: n ¼ 12; patient 2: n ¼ 5; patient 3: n ¼ 25), whereas recognition of non-modified primary leukemic cells differed between the T cell clones (4250 pg/ml IFN-g; patient 1: n ¼ 1; patient 2: n ¼ 1; patient 3: n ¼ 15) (Figure 3a and Supplementary Figure 1AB) . TCR Vb analysis demonstrated that the T cell clones expressed various different TCR Vb chains, illustrating that the CD4 þ T cell responses were polyclonal (data not shown).
To determine whether allo-reactive CD4 þ T cell clones were capable of lysing primary leukemic cells, a 20-h 51 Cr-release cytotoxicity assay was performed with 3, 3 and 30 T cell clones from patients 1, 2 and 3, respectively, selected for strong reactivity against leukemic-APC (Figure 3a and Supplementary Figure 1AB ). Specific lysis of leukemic-APC was observed for 2, 3 and 15 T cell clones from patients 1, 2 and 3, respectively CD4 þ T cells as mediators of anti-tumor immunity S Stevanović et al (patient 1: 62% ± 4%; patient 2: 32 ± 7%; patient 3: 34 ± 9%) ( Figure 3b and data not shown). Lysis of non-modified primary leukemic cells was detected for 1, 2 and 7 of these T cell clones (patient 1: 21%; patient 2: 27±1%; patient 3: 32±8%). None of the T cell clones from patient 1, but 2 T cell clones from patient 2 and 19 T cell clones from patient 3 showed specific lysis of patient EBV-LCL (patient 2: 35 ± 9%; patient 3: 50 ± 15%), whereas donor EBV-LCL were never lysed (patient 1: 3 ± 5%; patient 2: 0 ± 4%; patient 3: 3 ± 4%) (Figure 3b and data not shown).
To identify the HLA-class II restriction molecules, 5, 13 and 30 CD4 þ T cell clones from patients 1, 2 and 3, respectively, selected for strong reactivity against leukemic-APC were screened for recognition of donor EBV-LCL or Hela cells retrovirally transduced with the mismatched HLA-DR, -DQ and -DP alleles in IFN-g ELISA. CD4 þ T cell clones from patient 1 were shown to be directed against the mismatched HLA-DPB1*0101 allele (n ¼ 3) (Supplementary  Figure 1c) , whereas T cell clones from patient 2 were restricted by the mismatched HLA-DRB1*0405 allele (n ¼ 1) and Figure 1D) . T cell clones from patient 3 showed specific recognition of donor EBV-LCL transduced with HLA-DRB3*0101 (n ¼ 1), HLA-DQB1*0603 (n ¼ 22), HLA-DPB1*0301 (n ¼ 1) and HLA-DPB1*0401 (n ¼ 1) (Figure 3c ). HLA restriction elements could not be determined for 2, 8 and 5 T cell clones from patients 1, 2 and 3, respectively.
A number of CD4 þ T cell clones specific for mismatched HLA class II alleles not only recognized, but also lysed primary leukemic cells. One of 3 HLA-DPB1*0101-restricted CD4 þ T cell clone from patient 1, and 2 T cell clones from patient 2 specific for HLA-DRB1*0405 (n ¼ 1), and HLA-DPB1*0301 (n ¼ 1 of 3 tested) showed specific lysis of primary leukemic cells (data not shown). For patient 3, direct lysis of primary leukemic cells was observed for T cell clones specific for HLA-DRB3*0101 (n ¼ 1), DQB1*0603 (n ¼ 4 of 22 tested), DPB1*0301 (n ¼ 1) and DPB1*0401 (n ¼ 1). Recognition of primary leukemic cells in the absence of specific lysis was observed for one HLA-DPB1*0101-restricted CD4 þ T cell clone from patient 1, one HLA-DPB1*0301-restricted T cell clone from patient 2, and 8 HLA-DQB1*0603-restricted T cell clones from patient 3. No recognition and lysis of primary leukemic cells, but strong recognition and lysis of leukemic APC was detected for one HLA-DPB1*0101-restricted CD4 þ T cell clone from patient 1, one HLA-DPB1*0301-restricted T cell clone from patient 2, and 10 HLA-DQB1*0603-restricted T cell clones from patient 3.
In summary, these data show that cytokine-producing and cytolytic CD4 þ T cell clones reactive against primary leukemic cells and restricted by mismatched HLA-class II alleles were Figure 3 Functional analysis of the anti-tumor response. Reactivity of CD4 þ T cell clones isolated during the anti-tumor response from mice engrafted with leukemic cells of patient 3 was tested for cytokine production and cytolytic activity against leukemic-APC, primary leukemic cells, patient and donor EBV-LCL. (a) Recognition of patient leukemic cells by 102 CD4 þ T cell clones producing high (4250 pg/ml, n ¼ 30, Left) and low (o250 pg/ml, n ¼ 72, Right) levels of IFN-g on incubation with leukemic-APC is shown. Each dot represents the mean release of IFN-g (pg/ml) in 50 ml supernatants of duplicate wells by a single T cell clone. (b) Specific lysis of leukemic-APC, primary leukemic cells, patient and donor EBV-LCL is shown for all CD4 þ T cells clones with strong recognition of leukemic-APC (4250 pg/ml, Figure 3a -Left) as measured by IFN-g ELISA. Mean specific lysis of target cells (420% lysis) of quadruplicate wells at E/T ratios of 30:1 in a 20 h 51 Cr-release cytotoxicity assay is shown. Representative experiments out of 2 independent experiments are depicted. (c) Recognition of patient EBV-LCL, non-transduced and retrovirally transduced donor EBV-LCL with HLA-DRB1*1301, -DRB3*0101, -DQB1*0603, -DPB1*0301 and -DPB1*0401 by representative CD4 þ T cell clones is shown as the mean release of IFN-g (pg/ml) in 50 ml supernatants of duplicate wells. In total, one HLA-DR -restricted CD4 þ T cell clone, 22 HLA-DQ-restricted CD4 þ T cell clones and two HLA-DP-restricted CD4 þ T cell clones were identified. IFN-g production depicted, is a representative experiment out of two independent experiments.
CD4 þ T cells as mediators of anti-tumor immunity
S Stevanović et al isolated during the anti-tumor responses after CD4 þ DLI, illustrating that HLA-class II specific allo-reactive CD4 þ T cells functioned as direct effector cells in the eradication of leukemic cells.
In vitro induction of leukemic cells with an APC phenotype
As flowcytometric analysis revealed that leukemic cells after treatment with DLI acquired an APC phenotype in vivo, we analyzed whether leukemic cells could acquire an APC phenotype in vitro on interaction with leukemia-specific CD4 þ T cells. Co-culturing of leukemia-reactive HLA-DR, -DQ and -DP-restricted CD4 þ T cell clones (n ¼ 9) with primary leukemic cells from all three patients resulted in the induction of leukemic-APC phenotype, as measured by an increased expression of HLA-DR (2.0-fold (range 1.6-4.5), HLA-DQ (3.8-fold (1.8-5.6), HLA-DP (3.8-fold (2.0-9.6), CD54 (14.0-fold (6.5-21.9), as well as CD40 (3.6-fold (2.5-8.7) and CD86 (2.0-fold (1.3-3.1) (Figure 4a) . No or minor changes in phenotype of primary leukemic cells were observed when co-cultured with CD4 þ T cell clones that showed limited reactivity against primary leukemic cells or a non-specific CD4 þ T cell clone (data not shown). Furthermore, we observed that primary leukemic cells incubated with supernatants of activated CD4 þ T cells also acquired an APC phenotype. Analysis of the cytokine release profile of the allo-reactive CD4 þ T cell clones on stimulation with primary leukemic cells revealed that the CD4 þ T cell clones predominantly produced IFN-g, TNF-a and IL-13 (data not shown). Culturing of primary leukemic cells with these cytokines as single agents or in different combinations and concentrations showed that 
Discussion
Using a NOD/scid mouse model for human ALL, we investigated the capacity of CD4 þ T cells targeting HLA-class II mismatched molecules to act as sole mediators of anti-tumor immunity. We observed that adoptive transfer of highly purified human CD4 þ T cells, in the absence of any contaminating or residual CD8 þ T cells, led to induction of strong anti-tumor responses, and that leukemic cells were shown to acquire an APC phenotype in vivo on treatment with DLI. We initially investigated the anti-tumor effect of CD4 þ DLI by immunomagnetic depletion of CD8 þ T cells from the DLI, following the same approach as in human clinical studies. Using this depletion procedure, CD4 þ DLI from URD1 and URD2 contained only low numbers of contaminating CD8 þ T cells. Nevertheless, these low numbers of CD8 þ T cells expanded in vivo, and, therefore, similar as in the human studies, it remained unknown whether the anti-tumor effects were mediated by CD4 þ T cells or by contaminating CD8 þ T cells. To exclude the possibility that anti-tumor responses were mediated by contaminating CD8 þ T cells, we administered CD4 þ DLI obtained after positive isolation of CD4 þ CD8À T cells by flowcytometry. This highly purified CD4 þ DLI from URD3 did not contain CD8 þ T cells, and in vivo expansion of CD8 þ T cells was not observed. On in vivo administration of highly purified CD4 þ DLI, the emergence and kinetics of activated CD4 þ T cells corresponded to the disappearance of leukemic cells, thereby providing conclusive evidence that CD4 þ T cells are capable of mediating GvL effect.
The important role of CD4 þ T cells in supplying help for efficient induction of immune responses has been well established, although their role as effector cells has been less evident. [8] [9] [10] [11] In this CD4 þ DLI study, we demonstrated induction of polyclonal allo-reactive CD4 þ T cell responses directed against different mismatched HLA-class II molecules of the patients. A number of isolated CD4 þ T cell clones (HLA-DRB1/B3, -DQB1 and -DPB1-restricted) showed not only strong recognition, but also direct cytolytic activity against primary leukemic cells, indicating that these CD4 þ T cell clones functioned as effector cells in eradication of leukemic cells from the mice. In addition, HLA-class II-restricted CD4 þ T cell clones were isolated which produced high levels of IFN-g, but failed to show cytolysis against primary leukemic cells, suggesting that these CD4 þ T cell clones mainly contributed as helper cells to the magnitude and/or maintenance of the anti-tumor response. Finally, HLA-class II-restricted CD4 þ T cell clones were isolated which showed no or low recognition (and lysis) of primary leukemic cells, whereas strong recognition (and lysis) of leukemic cells with an APC phenotype was observed. Although these CD4 þ T cell clones may have contributed to the overall anti-tumor response by eliminating leukemic cells with more differentiated phenotype, they are not expected to induce a long-lasting curative effect by eradicating the malignant leukemic stem cell.
Professional APC are required for efficient induction of immune responses. [8] [9] [10] We showed that leukemic cells in mice treated with DLI acquired a leukemic-APC phenotype in vivo, whereas leukemic cells from non-treated mice remained unchanged, indicating that primary leukemic cells acquired an APC phenotype on interaction with T cells. This is supported by our in vitro experiments, demonstrating that co-culture of primary leukemic cells with leukemia-reactive, but not with non-reactive or non-specific, CD4 þ T cells induces a leukemic-APC phenotype. Based on these results, we postulate that alloreactive CD4 þ T cells have been induced in vivo by primary leukemic cells, and that these CD4 þ T cells had different roles in the anti-tumor response, as effector cells by directly eliminating leukemic cells, and as helper cells by producing cytokines and inducing leukemic cells with APC phenotype. This cross-talk between primary leukemic cells and specific CD4 þ T cells leading to induction of leukemic-APC may subsequently have had a significant role in the overall magnitude of the anti-tumor response, as illustrated by the isolation of a substantial number of T cell clones with selective recognition of leukemic-APC.
Common protocols for alloSCT with URD preferably match patients and donors at 10/10 HLA-alleles, including HLA-A, -B, -C, -DRB1 and -DQB1, whereas HLA-DPB1 and -DRB3/4/5 are not considered. 31 Disparity for HLA-class I loci and HLA-DRB1 has been associated with high risk of GvHD and poor survival, 32, 33 and is, therefore, preferentially avoided. Mismatching at HLA-DRB3, 34 -DQB1 and -DPB1 alleles 32, 33, 35 however, has been reported to less strongly adversely affect the outcome of alloSCT. In this study, we demonstrated involvement of mismatched HLA-DRB3, -DQB1 and -DPB1 alleles in the induction of anti-tumor immunity after CD4 þ DLI in a NOD/ scid mouse model for human ALL. This model therefore provides a platform to investigate in more detail the differential contribution of single or combined locus mismatches for HLA-DRB3, -DQB1 and -DPB1 alleles. We previously demonstrated that HLA-class II expression on non-hematopoietic cells, including fibroblasts and keratinocytes, can be upregulated on long-term culturing with IFN-g, and that expression levels are sufficient for recognition by alloreactive HLA-DP-specific CD4 þ T cells.
7,14 Therefore, we postulate that in the early posttransplantation period, HLA-class II expression on non-hematopoietic cells may be upregulated by proinflammatory cytokines produced at high levels as a result of tissue damage induced by transplant conditioning regimens or infections. Infusion of HLA-class II mismatched donor CD4 þ T cells in the early posttransplantation period may therefore have a high risk for the development of GvHD. Administration of these CD4 þ T cells late after T cell depleted alloSCT, when the systemic inflammatory environment has resolved, may limit the development of GvHD, whereas reactivity against HLA-class II þ leukemic cells may be preserved. This is supported by our previous study showing that allo-reactive HLA-DP-specific CD4 þ T cells mediated strong GvL reactivity with only minimal skin GvHD in a patient with refractory chronic B cell leukemia who responded to unmodified DLI administered late after HLA-DP mismatched T cell depleted alloSCT. 7, 30 However, on the basis of in vitro experiments in this manuscript, CD4 þ DLI administered late after T cell depleted alloSCT during overt leukemic relapse may also lead to development of GvHD owing to upregulation of HLA-class II expression on non-hematopoietic cells by proinflammatory cytokines produced by donor CD4 þ T cells on interaction with leukemic cells.
In conclusion, in this study, we have investigated and demonstrated the capacity of CD4 þ DLI to induce strong anti-tumor immunity against ALL and CML in lymphoid blast crisis. Allo-reactive CD4 þ T cells directed against mismatched HLA-class II molecules were shown to be capable of directly eliminating leukemic cells as T-effector cells and to exert T-helper functions by producing cytokines and activating leukemic cells to acquire an APC phenotype. Our study therefore emphasizes the clinical relevance of targeting HLAclass II molecules for allogeneic CD4 þ T cell-based immunotherapy of HLA-class II expressing malignancies after alloSCT.
